Selexis expands immuno-oncology alliance with Agenus

Harvard and Deerfield forge major research alliance
Credit: Shutterstock.com/ Goran Bogicevic

Swiss life sciences business, Selexis, has expanded its immune-oncology alliance with Angenus with the shining of additional commercial license agreements.

The new agreements will allow Agenus leverage Selexis’ modular SUREtechnology Platform for the rapid, stable and cost-effective production of its therapeutic proteins.

Yemi Onakunle, Selexis Vice President, Licensing and Business Development, said: “The Selexis team has a notable track record of success in helping our partners overcome protein-expression challenges and advance products rapidly and safely through the clinic to the market where they can be made available to patients in need.”

The Selexis SUREtechnology Platform improves the way mammalian cells are used in the discovery, development and manufacturing of recombinant proteins and drugs.

The platform provides key significant advantages over traditional approaches, enabling speed, high-yield, stability and flexibility.

Alex Duncan, Chief Technology Officer at Agenus, said: “Our fully integrated capabilities, from early discovery of protein therapeutics to GMP manufacturing, allows us to rapidly produce and clinically test promising new drug candidates thereby delivering innovation with speed.

“A critical step in this process is the in-house development of commercially viable cell-lines expressing novel and complex proteins,” said

“We have successfully used the Selexis’ platform to drive our lead anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) programs and are excited to partner with them to advance our novel single agent and multi-specific antibody programs.”